Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
MTVA
$1.64
$
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Next Earnings
2026-02-25
Beta
0.279
Average Volume
Market Cap
Last Dividend
CIK
0001638287
ISIN
US64132R5037
CUSIP
CEO
Heon Kim Hyung
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
9
IPO Date
2016-08-05
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference | CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. | PRNewsWire | 2026-02-17 09:01:00 |
| MetaVia Secures Dozens Of Patents Through 2041 For Obesity Drug | MetaVia Inc. (NASDAQ: MTVA) shares are up during Friday's premarket session as the company announced a strong global intellectual property portfolio supporting its lead asset, DA-1726. | Benzinga | 2026-02-13 12:39:00 |
| MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 | Intellectual Property Portfolio Includes 39 Granted and Pending Patents in the U.S. and Internationally, Providing Protection Into 2041, Unless Extended Further CAMBRIDGE, Mass., Feb. 13, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strong global intellectual property portfolio supporting lead asset DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity and related metabolic disorders. | PRNewsWire | 2026-02-13 08:31:00 |
| MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel | DeepMatcher® Platform Confirms Strong Inflammatory and Cardiometabolic Target Engagement, Supporting Development in MASH and Potential Type 2 Diabetes CAMBRIDGE, Mass., Feb. 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today provided an update on its ongoing collaboration with Syntekabio, Inc., an artificial intelligence (AI)-driven drug discovery company, leveraging their proprietary DeepMatcher® platform. | PRNewsWire | 2026-02-04 08:00:00 |
| MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option | CAMBRIDGE, Mass., Jan. 16, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the closing of its previously announced underwritten public offering of Class A Units and Class B Units for gross proceeds of approximately $9.3 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants. | PRNewsWire | 2026-01-16 16:01:00 |
| MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering | CAMBRIDGE, Mass., Jan. 15, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the pricing of its underwritten public offering of shares of common stock (or common stock equivalents) and Series C Warrants and Series D Warrants for gross proceeds of approximately $8.1 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants. | PRNewsWire | 2026-01-15 09:32:00 |
| MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile | Statistically Significant (p=0.006) Waist Circumference Reduction of 9.8 cm at Day 54 Significant Direct Hepatic Activity with a 23.7% Reduction in Liver Stiffness (VCTE) by Day 54 Strong Glycemic Response with a 12.3 mg/dL Fasted Glucose Reduction by Day 54 Robust Weight Loss with 9.1% Reduction (21.2 lbs) by Day 54 CAMBRIDGE, Mass., Jan. 5, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive statistically significant results from the 8-week (extended from four weeks) non-titrated 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. | PRNewsWire | 2026-01-05 08:30:00 |
| MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference | CAMBRIDGE, Mass. , Dec. 29, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference. | PRNewsWire | 2025-12-29 08:31:00 |
| MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement | CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that on December 19, 2025, it received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. | PRNewsWire | 2025-12-22 08:31:00 |
| MetaVia Inc. Announces 1-for-11 Reverse Stock Split | CAMBRIDGE, Mass. , Dec. 2, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia" or the "Company"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a 1-for-11 reverse stock split of its common stock, par value $0.001 ("common stock"), effective at 5:00 p.m. | PRNewsWire | 2025-12-02 08:45:00 |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Elliott Wave Strategy | 6.48% | 0.97 | 21 | 0.25 | 0.32 | 62.21 |
| Larry Williams PercentR Strategy | 4.46% | 1.97 | 22 | 0.94 | 0 | 4.92 |
| Williams PercentR Strategy | 4.06% | 1.98 | 27 | 0.78 | 0 | 4.52 |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xx% | x | xx | xxxxx | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxx% | xxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |